595 related articles for article (PubMed ID: 24317278)
1. Interaction of Shiga toxin 2 with complement regulators of the factor H protein family.
Poolpol K; Orth-Höller D; Speth C; Zipfel PF; Skerka C; de Córdoba SR; Brockmeyer J; Bielaszewska M; Würzner R
Mol Immunol; 2014 Mar; 58(1):77-84. PubMed ID: 24317278
[TBL] [Abstract][Full Text] [Related]
2. Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome.
Orth D; Khan AB; Naim A; Grif K; Brockmeyer J; Karch H; Joannidis M; Clark SJ; Day AJ; Fidanzi S; Stoiber H; Dierich MP; Zimmerhackl LB; Würzner R
J Immunol; 2009 May; 182(10):6394-400. PubMed ID: 19414792
[TBL] [Abstract][Full Text] [Related]
3. Role of complement in enterohemorrhagic Escherichia coli-Induced hemolytic uremic syndrome.
Orth-Höller D; Würzner R
Semin Thromb Hemost; 2014 Jun; 40(4):503-7. PubMed ID: 24799304
[TBL] [Abstract][Full Text] [Related]
4. Complement in typical hemolytic uremic syndrome.
Orth D; Würzner R
Semin Thromb Hemost; 2010 Sep; 36(6):620-4. PubMed ID: 20865638
[TBL] [Abstract][Full Text] [Related]
5. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis.
Morigi M; Galbusera M; Gastoldi S; Locatelli M; Buelli S; Pezzotta A; Pagani C; Noris M; Gobbi M; Stravalaci M; Rottoli D; Tedesco F; Remuzzi G; Zoja C
J Immunol; 2011 Jul; 187(1):172-80. PubMed ID: 21642543
[TBL] [Abstract][Full Text] [Related]
6. Shiga toxin-induced complement-mediated hemolysis and release of complement-coated red blood cell-derived microvesicles in hemolytic uremic syndrome.
Arvidsson I; Ståhl AL; Hedström MM; Kristoffersson AC; Rylander C; Westman JS; Storry JR; Olsson ML; Karpman D
J Immunol; 2015 Mar; 194(5):2309-18. PubMed ID: 25637016
[TBL] [Abstract][Full Text] [Related]
7. Anti-factor H autoantibody-associated hemolytic uremic syndrome: review of literature of the autoimmune form of HUS.
Dragon-Durey MA; Blanc C; Garnier A; Hofer J; Sethi SK; Zimmerhackl LB
Semin Thromb Hemost; 2010 Sep; 36(6):633-40. PubMed ID: 20865640
[TBL] [Abstract][Full Text] [Related]
8. New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab.
Köse O; Zimmerhackl LB; Jungraithmayr T; Mache C; Nürnberger J
Semin Thromb Hemost; 2010 Sep; 36(6):669-72. PubMed ID: 20865644
[TBL] [Abstract][Full Text] [Related]
9. Autoantibodies in haemolytic uraemic syndrome (HUS).
Skerka C; Józsi M; Zipfel PF; Dragon-Durey MA; Fremeaux-Bacchi V
Thromb Haemost; 2009 Feb; 101(2):227-32. PubMed ID: 19190803
[TBL] [Abstract][Full Text] [Related]
10. Complement activation in diseases presenting with thrombotic microangiopathy.
Meri S
Eur J Intern Med; 2013 Sep; 24(6):496-502. PubMed ID: 23743117
[TBL] [Abstract][Full Text] [Related]
11. Anti-Shiga toxin 2 antibodies in enterohemorrhagic Escherichia coli O104:H4 infected patients may predict hemolytic uremic syndrome.
Dammermann W; Mihajlov V; Middendorf B; Mellmann A; Karch H; Lüth S; Ullrich S
J Gastroenterol Hepatol; 2018 Jul; 33(7):1353-1356. PubMed ID: 29280264
[TBL] [Abstract][Full Text] [Related]
12. Complement factor H, FHR-3 and FHR-1 variants associate in an extended haplotype conferring increased risk of atypical hemolytic uremic syndrome.
Bernabéu-Herrero ME; Jiménez-Alcázar M; Anter J; Pinto S; Sánchez Chinchilla D; Garrido S; López-Trascasa M; Rodríguez de Córdoba S; Sánchez-Corral P
Mol Immunol; 2015 Oct; 67(2 Pt B):276-86. PubMed ID: 26163426
[TBL] [Abstract][Full Text] [Related]
13. Atypical hemolytic uremic syndrome-associated variants and autoantibodies impair binding of factor h and factor h-related protein 1 to pentraxin 3.
Kopp A; Strobel S; Tortajada A; Rodríguez de Córdoba S; Sánchez-Corral P; Prohászka Z; López-Trascasa M; Józsi M
J Immunol; 2012 Aug; 189(4):1858-67. PubMed ID: 22786770
[TBL] [Abstract][Full Text] [Related]
14. Promoter sequence of Shiga toxin 2 (Stx2) is recognized in vivo, leading to production of biologically active Stx2.
Bentancor LV; Mejías MP; Pinto A; Bilen MF; Meiss R; Rodriguez-Galán MC; Baez N; Pedrotti LP; Goldstein J; Ghiringhelli PD; Palermo MS
mBio; 2013 Oct; 4(5):e00501-13. PubMed ID: 24085779
[TBL] [Abstract][Full Text] [Related]
15. The interactive Factor H-atypical hemolytic uremic syndrome mutation database and website: update and integration of membrane cofactor protein and Factor I mutations with structural models.
Saunders RE; Abarrategui-Garrido C; Frémeaux-Bacchi V; Goicoechea de Jorge E; Goodship TH; López Trascasa M; Noris M; Ponce Castro IM; Remuzzi G; Rodríguez de Córdoba S; Sánchez-Corral P; Skerka C; Zipfel PF; Perkins SJ
Hum Mutat; 2007 Mar; 28(3):222-34. PubMed ID: 17089378
[TBL] [Abstract][Full Text] [Related]
16. Atypical hemolytic uremic syndrome due to factor H autoantibody.
Uslu-Gökceoğlu A; Doğan CS; Comak E; Koyun M; Akman S
Turk J Pediatr; 2013; 55(1):86-9. PubMed ID: 23692839
[TBL] [Abstract][Full Text] [Related]
17. Serum insulin-like growth factor-binding protein 2 levels as an indicator for disease severity in enterohemorrhagic
Tasaki Y; Inoue N; Shimizu M; Sugimoto N; Ishikawa S; Mizuta M; Yokoyama T; Kuroda M; Ohta K; Yachie A; Wada T
Ren Fail; 2021 Dec; 43(1):382-387. PubMed ID: 33641616
[TBL] [Abstract][Full Text] [Related]
18. The autoimmune disease DEAP-hemolytic uremic syndrome.
Skerka C; Zipfel PF; Müller D; Micklisch S; Riedl M; Zimmerhackl LB; Hofer J
Semin Thromb Hemost; 2010 Sep; 36(6):625-32. PubMed ID: 20865639
[TBL] [Abstract][Full Text] [Related]
19. Shiga toxin 2 reduces complement inhibitor CD59 expression on human renal tubular epithelial and glomerular endothelial cells.
Ehrlenbach S; Rosales A; Posch W; Wilflingseder D; Hermann M; Brockmeyer J; Karch H; Satchell SC; Würzner R; Orth-Höller D
Infect Immun; 2013 Aug; 81(8):2678-85. PubMed ID: 23690395
[TBL] [Abstract][Full Text] [Related]
20. Anti-factor H autoantibodies in C3 glomerulopathies and in atypical hemolytic uremic syndrome: one target, two diseases.
Blanc C; Togarsimalemath SK; Chauvet S; Le Quintrec M; Moulin B; Buchler M; Jokiranta TS; Roumenina LT; Fremeaux-Bacchi V; Dragon-Durey MA
J Immunol; 2015 Jun; 194(11):5129-38. PubMed ID: 25917093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
